Bluebird Bio Announces Completion of Its Q2 2024 Form 10-Q Filing

BusinesswireSep 27 16:30 ET

bluebird bio | 10-Q: Q2 2024 Earnings Report

SECSep 27 16:24 ET · Announcements

Bluebird Bio's Restructuring Efforts and Financial Outlook: A Cautious Hold Rating

TipRanksSep 27 13:15 ET · Ratings

Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns

Seeking AlphaSep 25 18:08 ET

Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo

Dow JonesSep 25 12:46 ET · Ratings

Bluebird Bio Analyst Ratings

BenzingaSep 25 12:35 ET · Ratings